Agarwalla, Pritha http://orcid.org/0000-0002-3425-6456
Ogunnaike, Edikan A.
Ahn, Sarah
Froehlich, Kristen A.
Jansson, Anton http://orcid.org/0000-0002-9362-8328
Ligler, Frances S. http://orcid.org/0000-0003-4909-2084
Dotti, Gianpietro http://orcid.org/0000-0002-2639-8526
Brudno, Yevgeny http://orcid.org/0000-0003-2963-3293
Funding for this research was provided by:
North Carolina Biotechnology Center (2019-FLG-3812, 2019-FLG-3812)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR002489, UL1TR002489)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R25-NS094093)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32CA196589, R21 CA229938, R01 CA193140, R37-CA260223)
Article History
Received: 24 June 2020
Accepted: 2 February 2022
First Online: 24 March 2022
Competing interests
: P.A., G.D. and Y.B. are inventors on patents related to the use of biomaterials for generation of CAR-T cell therapeutics. Y.B. receives an industry-sponsored research grant related to CAR-T cell therapeutic technology (unrelated to this work). G.D. is a paid consultant for Bellicum Pharmaceuticals, Tessa Therapeutics and Catamaran. The other authors declare no competing interests.